CN115607490A - Skin care composition for inhibiting sebaceous gland inflammation and preparation method thereof - Google Patents
Skin care composition for inhibiting sebaceous gland inflammation and preparation method thereof Download PDFInfo
- Publication number
- CN115607490A CN115607490A CN202211245534.1A CN202211245534A CN115607490A CN 115607490 A CN115607490 A CN 115607490A CN 202211245534 A CN202211245534 A CN 202211245534A CN 115607490 A CN115607490 A CN 115607490A
- Authority
- CN
- China
- Prior art keywords
- extract
- skin care
- care composition
- eucalyptus globulus
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 44
- 210000001732 sebaceous gland Anatomy 0.000 title claims abstract description 35
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 141
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract description 65
- 235000004692 Eucalyptus globulus Nutrition 0.000 claims abstract description 64
- 241000931143 Gleditsia sinensis Species 0.000 claims abstract description 59
- 241000132012 Atractylodes Species 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 244000116484 Inula helenium Species 0.000 claims description 35
- 235000002598 Inula helenium Nutrition 0.000 claims description 35
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- -1 dioctyldodecanol dimer linoleate Chemical class 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 6
- 235000019871 vegetable fat Nutrition 0.000 claims description 6
- 239000003925 fat Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 239000008169 grapeseed oil Substances 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- 235000020238 sunflower seed Nutrition 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 3
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 3
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 244000044822 Simmondsia californica Species 0.000 claims description 3
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 235000019868 cocoa butter Nutrition 0.000 claims description 3
- 229940110456 cocoa butter Drugs 0.000 claims description 3
- 235000019197 fats Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 229940119170 jojoba wax Drugs 0.000 claims description 3
- 229940049918 linoleate Drugs 0.000 claims description 3
- 239000010487 meadowfoam seed oil Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000010466 nut oil Substances 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 claims 1
- 206010000496 acne Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 25
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 24
- 208000020154 Acnes Diseases 0.000 abstract description 18
- 241001468182 Acidobacterium Species 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 90
- 230000000052 comparative effect Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 241000092665 Atractylodes macrocephala Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 241000533849 Gleditsia Species 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 229940055019 propionibacterium acne Drugs 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 235000013813 Gleditsia triacanthos Nutrition 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 3
- 229940035437 1,3-propanediol Drugs 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000132446 Inula Species 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical group OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 1
- 241000132011 Atractylodes lancea Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000735527 Eupatorium Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000009417 Helenium Nutrition 0.000 description 1
- 241000521915 Helenium Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a skin care composition for inhibiting sebaceous gland inflammation and a preparation method thereof, wherein the skin care composition comprises the following components in parts by weight: 10 parts of bighead atractylodes rhizome extract; 0.92-960 parts of a combination of Gleditsia sinensis extract, eucalyptus globulus extract and radix Inulae extract. The addition of Atractylodis rhizoma extract into Gleditsia sinensis extract, eucalyptus globulus Labill extract and radix Inulae extract can improve the effects of the skin care composition on inhibiting the growth of sebaceous gland cells, inhibiting Acidobacterium acnes and inhibiting new vessels; has effects of inhibiting red tide or red blood streak, controlling oil and removing acne, and can inhibit sebaceous gland inflammation.
Description
Technical Field
The application belongs to the technical field of daily cosmetics, and particularly relates to a skin care composition for inhibiting sebaceous gland inflammation and a preparation method thereof.
Background
Acne is a chronic inflammatory disease caused by the intrinsic defect of the sebaceous glands of the fur, and the main causes of acne include: hyperproliferation of hair follicle keratinocytes, hypersecretion of sebum, proliferation of acne-inducing bacteria such as acidobacterium acnes (Propionibacterium acnes), inflammation caused by sebaceous glands, and the like. Acne on the face is caused by the interaction of the above factors, causing substances in the hair follicles to flow out of the dermis.
The existing treatment methods generally comprise using preparations containing chemical components such as steroid hormones, benzoyl peroxide, azelaic acid, isotretinoin and the like, but the components can cause other problems such as safety and antibiotic resistance. Meanwhile, inflammatory factors secreted from the skin surface under the long-term stimulation of microorganisms can stimulate the skin immune system, cause the expansion of capillaries on the skin surface, show the phenomena of facial redness or pigmentation and the like on the skin surface, not only cause the problems of skin health, but also cause psychological damage. Therefore, improvements in related care products are still needed.
Disclosure of Invention
In view of the above, the present application provides a skin care composition for inhibiting sebaceous gland inflammation and a preparation method thereof, and aims to provide a skin care composition for inhibiting sebaceous gland cell growth, inhibiting lactobacillus acnes and inhibiting neovascularization.
In a first aspect, the embodiments of the present application provide a skin care composition for inhibiting sebaceous gland inflammation, comprising the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
0.92-960 parts of a combination of Gleditsia sinensis extract, eucalyptus globulus Labill extract and radix Inulae extract.
An embodiment according to one aspect of the application comprises the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
10-100 parts of a combination of a gleditsia sinensis extract, an eucalyptus globulus extract and an elecampane inula root extract.
An embodiment according to one aspect of the present application comprises the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
30-60 parts of a combination of a gleditsia sinensis extract, an eucalyptus globulus extract and an elecampane inula root extract.
According to an embodiment of one aspect of the present application, the mass ratio of the honey locust extract, the eucalyptus globulus labill extract and the elecampane inula root extract is: 1:0.92-960:0.92-960.
According to an embodiment of one aspect of the application, the skin care composition is in powder form and has an average particle size of 0.25 to 10 μm.
According to an embodiment of one aspect of the present application, the skin care composition has an ethanol content of 0.1ppm or less.
According to an embodiment of one aspect of the present application, the skin care composition further comprises a solvent selected from organic alcohols, water, vegetable fats or combinations thereof.
According to an embodiment of one aspect of the present application, the vegetable fat is selected from jojoba oil, sunflower seed oil, castor oil, coconut oil, grape seed oil, shea butter, meadowfoam seed oil, macadamia nut oil, olive oil, palm oil, squalane, cocoa butter, jojoba fat, glycolipids, octyldodecanol, caprylic/capric triglyceride, coco-caprylic/capric triglyceride, oleic/linoleic/linolenic polyglyceryl esters and dioctyldodecanol dimer linoleate or combinations thereof;
according to an embodiment of one aspect of the present application, the organic alcohol is selected from the group consisting of methyl propylene glycol, 1, 3-propanediol, 1, 3-butanediol, 1, 2-pentanediol, 1, 2-hexanediol, caprylyl glycol, ethyl hexyl glycerol, or combinations thereof.
According to an embodiment of one aspect of the present application, the skin care composition further comprises at least one of a moisturizer, a thickener, an emulsifier, a neutralizer and a preservative.
In a second aspect, the present application provides a method of making the skin care composition of the first aspect, comprising:
soaking Gleditsia sinensis powder, eucalyptus globulus Labill powder, radix Inulae powder and Atractylodis rhizoma powder in solvent respectively to obtain Gleditsia sinensis solution, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution;
stirring the Gleditsia sinensis extract, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution at 15-100 deg.C and 300-800rpm for 1-8 hr, filtering, and concentrating the filtrate to obtain Gleditsia sinensis extract, eucalyptus globulus Labill extract, radix Inulae extract and Atractylodis rhizoma extract;
mixing the Gleditsia sinensis extract, eucalyptus globulus extract, radix Inulae extract and Atractylodis rhizoma extract to obtain the skin care composition.
In a third aspect, the present application provides a method of making the skin care composition of the first aspect, comprising:
mixing and soaking gleditsia sinensis powder, eucalyptus globulus labill powder, elecampane powder and bighead atractylodes rhizome powder in a solvent to obtain a mixture;
stirring the mixture at the temperature of 15-100 ℃ and the rotating speed of 300-1000rpm for 1-24h, and then filtering to obtain a filtrate;
concentrating the filtrate to obtain the skin care composition.
According to an example of one aspect of the present application, the particle sizes of the honey locust powder, the eucalyptus globulus labill powder, the elecampane powder and the atractylodes macrocephala powder are 60-80 mesh, respectively.
According to an embodiment of one aspect of the application, the solvent is selected from water, ethanol or a combination thereof.
Compared with the prior art, the application has at least the following beneficial effects:
the present application provides a skin care composition for inhibiting sebaceous gland inflammation comprising: 10 parts of bighead atractylodes rhizome extract; 0.92-960 parts of a combination of Gleditsia sinensis extract, eucalyptus globulus extract and radix Inulae extract; the addition of Atractylodis rhizoma extract into Gleditsia sinensis extract, eucalyptus globulus Labill extract and radix Inulae extract can improve the effects of the skin care composition on inhibiting the growth of sebaceous gland cells, inhibiting Acidobacterium acnes and inhibiting new vessels; has effects of inhibiting red tide or red blood streak, controlling oil and removing acne, and can inhibit sebaceous gland inflammation.
Drawings
FIG. 1 shows a graph of the results of the sebaceous gland cell inhibitory activity provided herein;
fig. 2 shows a microscopic observation of neovascularization as provided herein.
Detailed Description
In order to make the application purpose, technical solution and beneficial technical effects of the present application clearer, the present application is further described in detail with reference to the following embodiments. It should be understood that the embodiments described in this specification are only for explaining the present application and are not intended to limit the present application.
For the sake of brevity, only a few numerical ranges are explicitly disclosed herein. However, any lower limit may be combined with any upper limit to form ranges not explicitly recited; and any lower limit may be combined with any other lower limit to form a range not explicitly recited, and similarly any upper limit may be combined with any other upper limit to form a range not explicitly recited. Also, although not explicitly recited, each point or individual value between endpoints of a range is encompassed within the range. Thus, each point or individual value can form a range not explicitly recited as its own lower or upper limit in combination with any other point or individual value or in combination with other lower or upper limits.
In the description of the present application, it is to be noted that, unless otherwise specified, "above" and "below" are inclusive of the present number, and "plural" of "one or more" means two or more.
The above summary of the present application is not intended to describe each disclosed embodiment or every implementation of the present application. The following description more particularly exemplifies illustrative embodiments. At various points throughout this application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the list is provided only as a representative group and should not be construed as exhaustive.
Acne, a type of chronic inflammatory disease caused by the self-localization of the sebaceous glands of the fur, occurs mainly as a result: acne on the face surface generally occurs by the flux of substances in hair follicles out of the dermis layer accompanying the interaction of the above factors, such as hyperproliferation of hair follicle keratinocytes, hyperseborrhea, proliferation of acne-inducing bacteria such as acidobacterium acnes (Propionibacterium acnes), and inflammation around sebaceous glands.
In the treatment of acne, preparations containing chemical components such as steroid hormones, benzoyl peroxide, azelaic acid and isotretinoin are generally used, which have the problems of potential safety hazards, antibiotic resistance and the like, and meanwhile, inflammatory factors secreted by long-term stimulation of skin surface microorganisms stimulate the skin immune system to cause the dilation of skin surface capillaries, which are manifested as phenomena such as facial redness or pigmentation in the skin surface and are unpleasant in appearance.
However, most of the development ideas of acne treatment or acne removal products are mostly focused on the primary bacteriostatic and anti-inflammatory stage, which is beneficial to solving the skin redness, pigmentation and facial red tide phenomena caused by the chronic inflammation reaction in the early stage of acne.
The inventors have studied and found that it is desirable to provide a product which can improve the appearance of skin by inhibiting bacteria and diminishing inflammation in the early stage and which does not use the chemical components having the safety risk and the resistance to antibiotics. Surprisingly, the inventors found that the addition of the extract of white atractylodes rhizome to the extract of honey locust, the extract of eucalyptus globulus and the extract of elecampane inula root can improve the acne removing, oil controlling and red blood streak inhibiting effects of the plant composition.
Skin care compositions
In a first aspect, the embodiments of the present application provide a skin care composition for inhibiting sebaceous gland inflammation, comprising the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
0.92-960 parts of a combination of Gleditsia sinensis extract, eucalyptus globulus Labill extract and radix Inulae extract.
Gleditsia sinensis (Gleditsia sinensis Lam.) also called Gleditsia sinensis Tree and fructus Gleditsiae Abnormalis, is a deciduous tree or small tree of Gleditsia of Leguminosae, has effects of eliminating phlegm, dredging orifice, relieving cough, inducing diuresis, relieving swelling, expelling pus, killing parasite, and treating tinea, and can be used for treating facial black nevus, small pimple, lump, miliaria and acne in folk, and can be used as topical preparation for inhibiting sebum secretion.
Eucalyptus globulus Labill, also known as "Eupatorium berry", is an arborvitae tree of Eucalyptus of Myrtaceae, and Eucalyptus globulus is due to its effective antibacterial, antioxidant, antiallergic and antiinflammatory pharmacological effects. In the application of skin care, the eucalyptus globulus labill extract is widely used as a raw material plant in the aspect of acne removing efficacy due to the strong antibacterial effect of the eucalyptus globulus labill extract on the acidobacillus acnes.
The elecampane inula root (Innula helenium L) is the root of elecampane inula root of the genus inula of the family Compositae, has warm, bitter and pungent properties, has the effects of strengthening the spleen and stomach, promoting the circulation of qi and removing blood stasis, regulating qi and resolving depression and the like, and has various effects of expelling parasites, resisting bacteria, reducing blood sugar and the like in physiological activity.
Atractylodis Rhizoma (Atractylodes rhizome, atractylodes japonica Koidz) is a perennial herb of Atractylodes of Compositae, has medicinal function of spleen-activating, bitter, warm, pungent and strong property, and has effects of eliminating dampness, eliminating turbid pathogen, and relieving pain.
According to the skin care composition provided by the embodiment of the application, the combination of 10 parts by weight of the bighead atractylodes rhizome extract and 0.92-960 parts by weight of the gleditsia sinensis lam extract, the eucalyptus globulus labill extract and the elecampane inula root extract has the effects of inhibiting the red tide and removing acnes, and the inhibition on the growth of sebaceous gland cells, the inhibition on the acnes caused by acidibacterium acnes and the inhibition on the new blood vessels are improved by adding the bighead atractylodes rhizome extract into the gleditsia sinensis lam, the eucalyptus globulus labill and the elecampane root extract. Can also be used for treating chronic inflammation such as acne.
In some embodiments, the following components are included in parts by weight:
10 parts of bighead atractylodes rhizome extract;
10-100 parts of a combination of a gleditsia sinensis extract, a eucalyptus globulus labill extract and an elecampane inula root extract.
In some embodiments, the following components are included in parts by weight:
10 parts of bighead atractylodes rhizome extract;
30-60 parts of a combination of a gleditsia sinensis extract, a eucalyptus globulus labill extract and an elecampane inula root extract. The combination of the atractylodes macrocephala koidz extract, the gleditsia sinensis lam extract, the eucalyptus globulus labill extract and the elecampane inula root extract in parts by weight can further improve the red tide inhibiting effect and the acne removing effect, and improve the sebaceous gland cell growth inhibiting effect, the acnes acidibacterium acnes inhibiting effect and the angiogenesis inhibiting effect.
In some embodiments, the weight ratio of the gleditsia sinensis extract, the eucalyptus globulus labill extract and the elecampane inula root extract is: 1:0.92-960:0.92-960. The mass ratio of the gleditsia sinensis extract to the eucalyptus globulus extractive to the elecampane inula root extract can be as follows: 1:1:1,1:32:1,1:32:32,1:20:1,1:1:20. Has effects in inhibiting red tide and removing acne.
According to an embodiment of one aspect of the application, the skin care composition is in powder form and has an average particle size of 0.25 to 10 μm. The powdered skin care composition has the effects of improving the stability and uniformity of the Atractylodis rhizoma extract, the Gleditsia sinensis extract, the Eucalyptus globulus Labill extract and the radix Inulae extract, further improving the effects of inhibiting red tide and removing acne, and further improving the effects of inhibiting the growth of sebaceous gland cells, inhibiting Acidobacterium acnes and inhibiting new vessels.
In some embodiments, the skin care composition has an ethanol content of 0.1ppm or less. In the skin care composition, the content of the ethanol is less than or equal to 0.1ppm, and the ethanol is little or not contained, so that the skin irritation, particularly the irritation to sensitive muscles, is avoided.
In some embodiments, the skin care composition further comprises a solvent selected from organic alcohols, water, vegetable fats, or combinations thereof. The skin care composition can be used in a water-soluble medium and an oil-soluble medium, has high compatibility and has a more common use scene.
In some embodiments, the vegetable oil is selected from jojoba oil, sunflower seed oil, castor oil, coconut oil, grape seed oil, shea butter, meadowfoam seed oil, macadamia nut oil, olive oil, palm oil, squalane, cocoa butter, jojoba fat, glycolipids, octyldodecanol, caprylic capric triglyceride, coco-caprylic capric triglyceride, oleic/linoleic/linolenic polyglycerides and dioctyldodecanol dimer linoleate, or a combination thereof. According to the embodiment of the present application, the vegetable oil or fat can ensure the safety, moisturizing property, fluidity and homogeneity of the skin care composition, and ensure the moisturizing effect. Wherein, the grape seed oil, the coconut oil and the sunflower seed oil also have antioxidant effect, can improve the repairing effect on the chapped skin and reduce the damage of ultraviolet rays.
In some embodiments, the organic alcohol is selected from methyl propylene glycol, 1, 3-propanediol, 1, 3-butanediol, 1, 2-pentanediol, 1, 2-hexanediol, octyl glycol, ethylhexyl glycerol, or a combination thereof. The skin care composition is dissolved in the organic alcohol, so that the skin care composition has good intersolubility and can improve the moisturizing effect of the composition.
In some embodiments, the skin care composition further comprises at least one of a humectant, a thickener, an emulsifier, a neutralizer, and a preservative. Any one or more additives can be added to the skin care composition, so that the skin care composition has corresponding functions and the use effect of the composition is improved.
In some embodiments, the humectant is selected from glycerin, butylene glycol, 1, 3-propanediol, 1, 2-pentanediol, caprylyl glycol, and sodium hyaluronate, or a combination thereof. The above moisturizer can enhance the moisturizing effect of the skin care composition for skin, and is well mixed with each component.
In some embodiments, the thickening agent is selected from carbomers, acrylic polymers crosslinked with C10-C30 alkanol acrylate, xanthan gum, or combinations thereof. The thickening agents described above have important effects on the thickening, stability and rheology of skin care compositions for the skin; by using thickeners in different weight ratios, the skin care composition for skin can be in a liquid state, a paste state, or a gel state to be suitable for different scenes. The skin care composition has good thickness and excellent spreadability and extensibility due to the adoption of the thickening agent in a proper proportion.
In some embodiments, the plant emulsifier is selected from polyglyceryl-3 diisostearate, polyglyceryl 2-dipolyhydroxystearate, polyglyceryl-2 isostearate, polyglyceryl 4-isostearate, polyglyceryl 3-polyricinoleate, polyglyceryl 6-polyricinoleate, glyceryl stearate, sorbitan isostearate, sorbitan oleate and sucrose cocoate or a combination thereof. The plant emulsifier is plant-derived, green and safe, has no stimulation to skin, is suitable for sensitive muscle user groups, and has good anti-allergy and relieving effects. The polyglycerol stearate can form a lamellar liquid crystal type colloid network structure in an emulsification system, so that the stability of the emulsification system is improved. The polyglycerol-3 diisostearate and the polyglycerol 2-dipolyhydroxystearate have stronger emulsifying capacity, can wrap more water phase by less oil phase, has good dispersibility and stability, and has better compatibility with various water-in-oil system emulsifiers.
In some embodiments, the neutralizing agent is selected from sodium hydroxide, potassium hydroxide, or a combination thereof. By adding the neutralizing agent, the pH of the skin care composition for skin can be controlled to be more suitable for the skin of different users.
In some embodiments, the preservative is selected from phenoxyethanol, p-hydroxyacetophenone, 1, 2-pentanediol, 1, 2-hexanediol, p-anisic acid, caprylyl glycol, ethylhexyl glycerin, benzoic acid, sodium benzoate, caprylyl hydroxamic acid, or combinations thereof. The preservative is well compatible with other substances, and the shelf life of the skin care composition for skin can be prolonged and shelf life of the skin care composition can be prolonged by adding the preservative.
The skin care composition according to the present application may further comprise a combination of one or more of a radical scavenger, a chelating agent, an antioxidant, a film former, a stabilizer, a fragrance, a pigment, preferably, the stabilizer comprises one or more of sodium chloride, magnesium chloride and magnesium sulfate, and the chelating agent comprises EDTA-2Na and/or EDTA-4Na.
In some embodiments, the skin care composition can further comprise a skin immune enhancer of natural origin, such as sodium hyaluronate, bisabolol, cucumis sativus fruit extract, bergamot extract, cornflower extract, or a combination thereof. The skin immunity promoter is safe and healthy, and can improve skin immunity. The carboxymethyl B-glucan salt may be sodium carboxymethyl B-glucan, potassium carboxymethyl B-glucan, or the like.
The invention also provides application of the skin care composition in skin care products, preferably the skin care products comprise water-type skin care products, gel-type skin care products, emulsion-type skin care products, essence-type skin care products or cream-type skin care products.
Method for preparing skin care composition
In a second aspect, the present application provides a method of making the skin care composition of the first aspect, comprising:
soaking Gleditsia sinensis powder, eucalyptus globulus Labill powder, radix Inulae powder and Atractylodis rhizoma powder in solvent respectively to obtain Gleditsia sinensis solution, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution;
stirring the Gleditsia sinensis solution, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution at 15-100 deg.C and 300-800rpm for 1-8 hr, respectively, filtering, and concentrating the filtrate to obtain Gleditsia sinensis extract, eucalyptus globulus Labill extract, radix Inulae extract and Atractylodis rhizoma extract;
mixing the Gleditsia sinensis extract, eucalyptus globulus extract, radix Inulae extract and Atractylodis rhizoma extract to obtain the skin care composition.
Stirring at 300-800rpm at 15-100 deg.C for 1-8 hr to further improve dissolution of effective active substances in Gleditsia sinensis solution, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution, and improve effective active components thereof.
According to the embodiment of the application, the gleditsia sinensis extract, the eucalyptus globulus labill extract, the elecampane inula root extract and the bighead atractylodes rhizome extract are prepared and then mixed, and the mixture can be mixed according to the required proportion, so that the specific mass ratio and the corresponding effect are further achieved.
In a third aspect, the present application provides a method of making the skin care composition of the first aspect, comprising:
mixing and soaking gleditsia sinensis powder, eucalyptus globulus labill powder, elecampane inula root powder and atractylodes macrocephala powder in a solvent to obtain a mixture;
stirring the mixture at the temperature of 15-100 ℃ and the rotating speed of 300-1000rpm for 1-24h, and then filtering to obtain filtrate;
concentrating the filtrate to obtain the skin care composition.
The mixture of the gleditsia sinensis extract, the eucalyptus globulus extract, the elecampane inula root extract and the bighead atractylodes rhizome extract is prepared, so that the steps of respective extraction can be reduced, and the efficiency can be improved.
In some embodiments, the gleditsia sinensis powder, eucalyptus globulus labill powder, elecampane powder and atractylodes macrocephala powder have a particle size of 60-80 mesh, respectively. The granularity of the gleditsia sinensis powder, the eucalyptus globulus labill powder, the elecampane powder and the atractylodes macrocephala powder is in the range, so that the effective active components in the gleditsia sinensis powder can be dissolved out at a proper temperature and at a proper stirring speed, the preparation efficiency is improved, and the content of the effective active components is improved.
In some embodiments, the solvent is selected from water, ethanol, or a combination thereof. The extract is extracted by water and ethanol, so that the loss of raw materials can be reduced, and the preparation cost can be saved.
In some embodiments, the weight ratio of the gleditsia sinensis powder, the eucalyptus globulus labill powder and the elecampane inula root powder is 1:0.92-960, the above-mentioned quality combination ratio can control oil and inhibit acne bacillus and skin red blood silk together with the white atractylodes rhizome extract.
The preparation method of the skin care composition can be used for preparing the skin care composition, the process is simple, the time consumption is short, the requirement on equipment is low, the prepared skin care composition system is stable, the harm to the body health of a user can not be caused, and the skin care composition has great large-scale application potential.
Examples
The present disclosure is more particularly described in the following examples that are intended as illustrative only, since various modifications and changes within the scope of the present disclosure will be apparent to those skilled in the art. Unless otherwise indicated, all parts, percentages, and ratios reported in the following examples are on a weight basis, and all reagents used in the examples are commercially available or synthesized according to conventional methods and can be used directly without further treatment, and the equipment used in the examples is commercially available.
Examples 1 to 4
This example provides a method of making a skin care composition comprising: crushing the gleditsia sinensis, the eucalyptus globulus, the elecampane and the bighead atractylodes rhizome into powder by using a wall breaking machine respectively, sieving the powder with a 80-mesh sieve for later use, and soaking crushed and filtered gleditsia sinensis, the eucalyptus globulus, the elecampane and the bighead atractylodes rhizome in mixed liquid of 70 parts of ethanol and 30 parts of distilled water respectively, wherein the volume of the mixed liquid is about 20 times of the mixed volume of each crushed and filtered substance. Stirring was carried out at 600rpm for 3h at 25. + -. 2 ℃ respectively. Filtering to remove solid residue, concentrating the filtrate under reduced pressure until ethanol is removed to obtain Gleditsia sinensis extract, eucalyptus globulus Labill extract, radix Inulae extract and Atractylodis rhizoma extract.
Mixing the obtained 4 extracts according to the mass ratio shown in the following table to obtain the skin care composition.
Table 1 weight ratio of the honey locust extract, the eucalyptus globulus labill extract, the elecampane inula root extract and the atractylodes macrocephala extract in examples 1-4 (unit: each part is kg).
Examples 5 to 10
This example provides a method of making a skin care composition comprising:
crushing the gleditsia sinensis, the eucalyptus globulus, the elecampane and the bighead atractylodes rhizome into powder by using a wall breaking machine, and sieving the powder by using a 60-80-mesh sieve for later use. Taking the gleditsia sinensis powder, the eucalyptus globulus labill powder, the elecampane powder and the atractylodes macrocephala powder according to the mass ratio for later use. Soaking the above powders in 1-20 times of the volume of the mixture. The components of the mixture are water and alcohol. Stirring at 300-1000rpm at 15-100 deg.C for 1-24 hr, and extracting the above raw materials under stirring. Filtering to remove solid residue, and concentrating the filtrate under reduced pressure until ethanol is removed to obtain skin care extract. The mass ratio of the gleditsia sinensis lam, the eucalyptus globulus, the elecampane powder and the atractylodes macrocephala powder is shown in table 2.
Table 2 weight ratio (unit, kg) of the honey locust powder, the eucalyptus globulus labill powder, the elecampane inula root powder and the atractylodes macrocephala powder in examples 5-10.
Comparative example 1
This comparative example provides a method of preparing a skin care composition comprising: crushing the gleditsia sinensis, the eucalyptus globulus and the elecampane into powder by using a wall breaking machine, sieving the powder with a 80-mesh sieve for later use, respectively soaking crushed and filtered gleditsia sinensis, the eucalyptus globulus and the elecampane into mixed liquor with the volume of 20 times, wherein the mixed liquor comprises 70 parts of ethanol and 30 parts of distilled water. Stirring was carried out at 600rpm for 3h at 25. + -. 2 ℃. Filtering to remove solid residue, and concentrating the filtrate under reduced pressure until ethanol is removed to obtain Gleditsia sinensis extract, eucalyptus globulus Labill extract and radix Inulae extract. The obtained 3 extracts are mixed according to the weight proportion of 25 parts: 25 parts of: after mixing in a ratio of 25 parts, a skin care composition is obtained.
Comparative example 2
The comparative example provides a preparation method of a skin care composition, wherein bighead atractylodes rhizome is crushed into powder by a wall breaking machine, the powder is sieved by a 80-mesh sieve for later use, and the powder is soaked in a mixed solution with the volume 20 times that of the mixed solution, and the mixed solution comprises 70 parts of ethanol and 30 parts of distilled water. Stirring was carried out at 600rpm for 3h at 25. + -. 2 ℃. Filtering to remove solid residue, and vacuum concentrating the filtrate until no ethanol is contained to obtain Atractylodis rhizoma extract. I.e., the skin care composition of this comparative example.
Test section
1) Sebaceous gland cell growth rate test
After the sebaceous gland cells undergo a differentiation process for about one week, the cortical cells mature, and sebum is removed through the cortical tubes. The inhibitory effect of examples 1 to 10 and comparative example 1 on sebaceous gland cells was preliminarily evaluated by the sebaceous gland cell proliferation inhibitory potency test method.
Taking logarithmHuman sebaceous gland cells (SZ 95) in the growth phase, digested with 0.25% pancreatic enzyme, collected and counted in a 96-well plate at 5X10 4 cells/mL were seeded at a cell density of about 60-70% per well 48h after plating, in medium: DMEM +10% FBS +1% P/S, culture conditions: 37 ℃ C., 5% CO 2 The culture is carried out under the condition of content, and the activity meets the requirement. The experimental groups were divided into 12 groups, a control group, and examples 1 to 10 and comparative examples 1 to 2.DMEM is a medium containing various amino acids and glucose, FBS stands for fetal bovine serum, and P/S stands for penicillin/streptomycin. The control group was treated with serum-free medium for 1,3,5 days, respectively.
The samples of examples 1 to 10 and comparative examples 1 to 2 were prepared as aqueous solutions having mass concentrations of 10. Mu.g/mL, 50. Mu.g/mL, and 100. Mu.g/mL, respectively. And (3) dropwise adding 100ug of the sample aqueous solution into a cell culture dish, continuously and respectively culturing for 1,3 and 5 days, adding 20 mu L of CCK8 solution in the CCK8 kit into each hole, incubating for 2 hours, measuring the light absorption value at the position of 570nm of wavelength by using an ultraviolet spectrophotometer, performing 3 parallel experiments, and taking the average value. The absorbance was recorded and the calculated cell growth rate is shown in table 3 and fig. 1.
TABLE 3 test results for% sebaceous gland cell growth rate
Calculating the cell growth rate according to the obtained light absorption value, wherein the calculation mode is as follows:
tx: sample treatment time (1, 3,5 days)
Examples 1-4 and comparative example 1 the concentrations to be measured were 10. Mu.g/mL, 50. Mu.g/mL, 100. Mu.g/mL;
independent sample t-tests using SPSS22.0 software were significantly different with p < 0.05. Here, the experimental group Tx OD570 value represents the absorbance at 570nm wavelength.
As can be seen from the above table, the sebaceous gland cells cultured in the absence of serum had no inhibitory effect, and the extracts of the examples and comparative examples had inhibitory effects on the sebaceous gland cells with increasing concentrations.
Examples 1-8 showed significantly stronger inhibitory effects on sebaceous gland cells than comparative examples 1-2, due to the addition of Atractylodis rhizoma extract to Gleditsia sinensis extract, eucalyptus globulus Labill extract and Inula helenia extract.
Examples 9 and 10 in the more extreme case, the inhibition of sebaceous gland cells was observed compared to the control group, and the compositions used in high concentrations required appropriate dilution. In example 4, the inhibitory activity of the sebaceous gland cell growth at the first day treatment time at a concentration of 100. Mu.g/ml is preferable, and the sebaceous gland cell growth rate is 23%.
2) Propionibacterium acnes zone of inhibition test
Acidibacterium acnes (Propionibacterium acnes), which is one of the genus lactobacilli and causes acne, were subjected to zone of inhibition tests using the skin care compositions of example 1 and comparative example 1.
Inoculating the preserved Propionibacterium acnes (ATCC 6919) into BHI liquid culture medium under aseptic condition, culturing at 37 deg.C in anaerobic incubator for 48 hr, centrifuging, resuspending, and adjusting Propionibacterium acnes concentration to 1X10 6 CFU/ml, spare. Taking sterile culture dishes with the diameter of 90mm in a sterile environment, introducing 20mL of BHI melting culture medium into each culture dish, cooling and fixing, uniformly coating 100 mu l of resuspended Acidobacterium acnes solution on the culture medium, taking circular filter paper with the diameter of 7mm to dip test drugs, respectively diluting comparative example 1 and examples 1-4 into 0.5% concentration, respectively preparing a blank control group and a positive control group, uniformly placing the filter paper dipped with the test drugs on the BHI solid culture medium coated with the Acidobacterium acnes, respectively carrying out 3 parallels, sealing the culture dishes by using sealing films, horizontally inverting the culture dishes in an anaerobic incubator at 37 ℃ for 20 hours, measuring the diameter of a bacteriostatic ring, and calculating the average diameter of the bacteriostatic ring of each test drug. The results are shown in Table 4.
The skin care compositions of examples 1-4 and comparative example 1 were present at 0.5% in the BHI melt medium;
the blank control group is PBS solution;
the positive control group was 0.1% triclosan.
Table 4 results for the zone of inhibition of acidibacterium acnes.
The results are shown in Table 4, where the inhibition zone was not shown by the sterile PBS treatment, the diameter of the inhibition zone of 0.1% tris-hydroxydiphenyl ether in the positive control group was 40.3mm, the diameter of the inhibition zone of comparative example 1 was 15.9mm, the diameter of the inhibition zone of example 1 was 18.7mm, the diameter of the inhibition zone of example 2 was 20.1mm, the diameter of the inhibition zone of example 3 was directly 19.2mm, and the diameter of the inhibition zone of example 4 was 20.7mm. Comparative example 1 and examples 1 to 4 both showed inhibition zones against acnes, and examples 1 to 4 were larger in diameter than comparative example 1, wherein example 4 had a better inhibition effect.
3) Neovascularization assay
Continuous or excessive application of steroid hormone preparations to inflammatory reaction of acne patients, weakening of skin vessel wall, expansion of capillary, exposure of capillary to skin surface, or appearance of facial redness or flush, etc. can be evaluated for the inhibition of angiogenesis in comparative examples 1-2 and examples 1-4.
Matrigel was added to a pre-cooled 96-well plate and transferred to 37 ℃ for incubation for 30min to allow the matrigel to polymerize. Adding the sample to the polymerized matrigel, and removing CO at 37 deg.C and 5% of the total 2 Incubate for another 30min at ambient. Then, human Umbilical Vein Endothelial Cells (HUVEC) in logarithmic growth phase were taken, digested with 0.25% pancreatin, collected and cultured at 1.5X10 per well 4 Inoculating the cells at a cell/well inoculation rate of 5% CO at 37 ℃ with saturated humidity 2 After 8h incubation in the incubator, the formation of new vessels was collected microscopically and the number of new vessels formed was counted.
Examples 1-4 and comparative example 1 had a concentration of 50. Mu.g/mL in the mixture per well plate; the control group was the same volume of distilled water.
The neovasculature of the control group, comparative example 1 and examples 1-4 was observed under an electron microscope as shown in FIG. 2. After 8h incubation, the vessels generated in comparative example 1 and example 1 have looser distance between the vessels and incomplete linking degree compared with the control group, and the comparison of examples 1-4 shows that the phenomenon is more obvious in example 1, which indicates that example 4 has the best effect on inhibiting the neovascularization.
Table 5 number of neovessels per well in well plates (averaged).
| Group of | Number of formed tubes |
| Control group | 68 |
| Comparative example 1 | 53 |
| Comparative example 2 | 51 |
| Example 1 | 45 |
| Example 2 | 32 |
| Example 3 | 29 |
| Example 4 | 26 |
The results of formation of new blood vessels in the control group, comparative examples 1-2 and examples 1-4 are shown in Table 5, and the numbers of formed vessels were 68, 53, 51, 45, 32, 29 and 26, respectively, indicating that the formation of new blood vessels was inhibited in comparative examples 1-2 and examples 1-4, and the neovascularization inhibitory ability of examples 1-4 was greater than that of comparative examples 1-2, in which the inhibitory effect of example 4 was more excellent.
In conclusion, the skin care composition of the present application has the effects of inhibiting red tide and removing acne, and the best effect of example 4 is obtained by evaluating the effects of sebaceous gland cell growth inhibition, acidibacterium acnes inhibition and neovascularization inhibition in different mixing ratios of 4 plants using the gleditsia sinensis, eucalyptus globulus, elecampane and atractylodes macrocephala as raw material plants.
The above description is only for the specific embodiments of the present application, but the scope of the present application is not limited thereto, and any person skilled in the art can easily think of various equivalent modifications or substitutions within the technical scope of the present application, and these modifications or substitutions should be covered within the scope of the present application. Therefore, the protection scope of the present application shall be subject to the protection scope of the claims.
Claims (10)
1. A skin care composition for inhibiting sebaceous gland inflammation comprises the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
0.92-960 parts of a combination of Gleditsia sinensis extract, eucalyptus globulus Labill extract and radix Inulae extract.
2. The skin care composition according to claim 1, comprising the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
10-100 parts of a combination of a gleditsia sinensis extract, an eucalyptus globulus extract and an elecampane inula root extract.
3. The skin care composition according to claim 1, comprising the following components in parts by weight:
10 parts of bighead atractylodes rhizome extract;
30-60 parts of a combination of a gleditsia sinensis extract, a eucalyptus globulus labill extract and an elecampane inula root extract.
4. The skin care composition according to claim 1, wherein the weight ratio of the gleditsia sinensis extract, the eucalyptus globulus labill extract and the elecampane inula root extract is: 1:0.92-960:0.92-960.
5. The skin care composition according to claim 1, wherein the skin care composition is in a powder form and has an average particle size of 0.25 to 10 μm.
6. The skin care composition according to any one of claims 1-5, wherein the amount of ethanol in the skin care composition is less than or equal to 0.1ppm.
7. The skin care composition of claim 6, further comprising a solvent selected from the group consisting of organic alcohols, water, vegetable fats and oils, and combinations thereof.
8. The skin care composition of claim 7, wherein the vegetable oil or fat is selected from jojoba oil, sunflower seed oil, castor oil, coconut oil, grape seed oil, shea butter, meadowfoam seed oil, macadamia nut oil, olive oil, palm oil, squalane, cocoa butter, jojoba fat, glycolipids, octyldodecanol, caprylic/capric triglyceride, coco-caprylic/capric triglyceride, oleic/linoleic/linolenic polyglyceryl esters, and dioctyldodecanol dimer linoleate, or combinations thereof;
the organic alcohol is selected from methyl propylene glycol, 1, 3-butylene glycol, 1, 2-pentanediol, 1, 2-hexanediol, octyl glycol, ethylhexyl glycerol or a combination thereof;
the skin care composition further comprises at least one of a humectant, a thickener, an emulsifier, a neutralizer, and a preservative.
9. A method of making a skin care composition according to any one of claims 1 to 8 comprising:
soaking Gleditsia sinensis powder, eucalyptus globulus Labill powder, radix Inulae powder and Atractylodis rhizoma powder in solvent respectively to obtain Gleditsia sinensis solution, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution;
stirring the Gleditsia sinensis solution, eucalyptus globulus Labill solution, radix Inulae solution and Atractylodis rhizoma solution at 15-100 deg.C and 300-800rpm for 1-8 hr, respectively, filtering, and concentrating the filtrate to obtain Gleditsia sinensis extract, eucalyptus globulus Labill extract, radix Inulae extract and Atractylodis rhizoma extract;
mixing the Gleditsia sinensis extract, eucalyptus globulus extract, radix Inulae extract and Atractylodis rhizoma extract to obtain the skin care composition.
10. A method of making a skin care composition according to any of claims 1-8 comprising:
mixing and soaking gleditsia sinensis powder, eucalyptus globulus labill powder, elecampane powder and bighead atractylodes rhizome powder in a solvent to obtain a mixture;
stirring the mixture at the temperature of 15-100 ℃ and the rotating speed of 300-1000rpm for 1-24h, and then filtering to obtain filtrate;
concentrating the filtrate to obtain the skin care composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211245534.1A CN115607490B (en) | 2022-10-12 | Skin care composition for inhibiting sebaceous gland inflammation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211245534.1A CN115607490B (en) | 2022-10-12 | Skin care composition for inhibiting sebaceous gland inflammation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115607490A true CN115607490A (en) | 2023-01-17 |
| CN115607490B CN115607490B (en) | 2024-06-28 |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117045563A (en) * | 2023-09-28 | 2023-11-14 | 云南英格生物技术有限公司 | Radix aucklandiae root extract and its preparation method and application |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186457A (en) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | Tryptase activity inhibitor and its utilization |
| KR20100066784A (en) * | 2008-12-10 | 2010-06-18 | (주)아모레퍼시픽 | Cosmetic composition for controlling anti-acne and anti-comed |
| KR20100123456A (en) * | 2009-05-15 | 2010-11-24 | 애경산업(주) | Composition for inhibiting sebum secretion and composition for preventing and improving acnes and dermatitis |
| CN103041194A (en) * | 2012-12-29 | 2013-04-17 | 青岛恒波仪器有限公司 | Traditional Chinese medicine composition for curing chronic eczema and preparation method thereof |
| CN104688811A (en) * | 2014-12-29 | 2015-06-10 | 昆明皕凯科技有限公司 | Acne removal composition based on natural plant raw materials and application thereof |
| CN105078829A (en) * | 2015-08-28 | 2015-11-25 | 青岛海之源智能技术有限公司 | Chinese medicinal acne-removing face cream and preparation method thereof |
| CN107080722A (en) * | 2017-03-28 | 2017-08-22 | 佛山市汇汾化妆品科技有限公司 | A kind of Whelk-eliminating paste |
| CN108653136A (en) * | 2018-06-26 | 2018-10-16 | 戴伟 | A kind of Chinese medicine composition and its mixed extract being used for cosmetics frost breast and facial mask |
| CN109260344A (en) * | 2018-11-14 | 2019-01-25 | 长沙联晶网络科技有限公司 | A kind of herbal composite and preparation method thereof for skin care |
| KR20210132346A (en) * | 2020-04-27 | 2021-11-04 | 박민희 | Cosmetic composition for salleviating skin itching and preventing or improving skin damage due to burns |
| CN114306511A (en) * | 2021-12-13 | 2022-04-12 | 宁夏职业技术学院（宁夏广播电视大学） | Compound composition and application thereof in preparing medicine for preventing and treating skin diseases caused by malassezia bacteria |
| CN114796038A (en) * | 2021-12-30 | 2022-07-29 | 广州端木生物科技有限公司 | Composition for rapidly removing acne, sterilizing and removing mites as well as preparation method and application thereof |
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186457A (en) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | Tryptase activity inhibitor and its utilization |
| KR20100066784A (en) * | 2008-12-10 | 2010-06-18 | (주)아모레퍼시픽 | Cosmetic composition for controlling anti-acne and anti-comed |
| KR20100123456A (en) * | 2009-05-15 | 2010-11-24 | 애경산업(주) | Composition for inhibiting sebum secretion and composition for preventing and improving acnes and dermatitis |
| CN103041194A (en) * | 2012-12-29 | 2013-04-17 | 青岛恒波仪器有限公司 | Traditional Chinese medicine composition for curing chronic eczema and preparation method thereof |
| CN104688811A (en) * | 2014-12-29 | 2015-06-10 | 昆明皕凯科技有限公司 | Acne removal composition based on natural plant raw materials and application thereof |
| CN105078829A (en) * | 2015-08-28 | 2015-11-25 | 青岛海之源智能技术有限公司 | Chinese medicinal acne-removing face cream and preparation method thereof |
| CN107080722A (en) * | 2017-03-28 | 2017-08-22 | 佛山市汇汾化妆品科技有限公司 | A kind of Whelk-eliminating paste |
| CN108653136A (en) * | 2018-06-26 | 2018-10-16 | 戴伟 | A kind of Chinese medicine composition and its mixed extract being used for cosmetics frost breast and facial mask |
| CN109260344A (en) * | 2018-11-14 | 2019-01-25 | 长沙联晶网络科技有限公司 | A kind of herbal composite and preparation method thereof for skin care |
| KR20210132346A (en) * | 2020-04-27 | 2021-11-04 | 박민희 | Cosmetic composition for salleviating skin itching and preventing or improving skin damage due to burns |
| CN114306511A (en) * | 2021-12-13 | 2022-04-12 | 宁夏职业技术学院（宁夏广播电视大学） | Compound composition and application thereof in preparing medicine for preventing and treating skin diseases caused by malassezia bacteria |
| CN114796038A (en) * | 2021-12-30 | 2022-07-29 | 广州端木生物科技有限公司 | Composition for rapidly removing acne, sterilizing and removing mites as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 天津市中医药研究院编: "《中国传统医药研究》", 中医古籍出版社, pages: 388 - 389 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117045563A (en) * | 2023-09-28 | 2023-11-14 | 云南英格生物技术有限公司 | Radix aucklandiae root extract and its preparation method and application |
| CN117045563B (en) * | 2023-09-28 | 2023-12-29 | 云南英格生物技术有限公司 | Radix aucklandiae root extract and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4589483B2 (en) | Acne preventive and therapeutic agent | |
| CN105326730B (en) | A kind of acne-removing composition and preparation method thereof containing Chinese herbal medicine extract | |
| CN105902408B (en) | Cosmetic composition containing brown alga and red algae essence | |
| CN111888318A (en) | Skin repairing, whitening and acne removing mask and preparation method thereof | |
| CN105496901A (en) | Cosmetic composition with anti-aging effect as well as preparation method and application thereof | |
| CN111529470B (en) | Compound acne-removing and allergy-relieving gel and preparation method thereof | |
| CN105434195B (en) | A kind of composition and its application with anti-acne and suppression pockmark systematic function | |
| KR20110057895A (en) | Skin external composition for promoting the production of hyaluronic acid containing ginsenoside re and ginsenoside compound k | |
| CN115317417A (en) | Composition containing guaiacum extract for repairing acne sensitive muscle and skin care product thereof | |
| KR101827771B1 (en) | Cosmetic composition containing Broussonetia extract for improving acne | |
| EP1328283A1 (en) | Skin external preparation containing pine pollen or pine pollen extract | |
| CN109157470A (en) | A kind of pox-dispelling function whitening skin-protection cream and preparation method thereof | |
| CN110974775A (en) | Allergy-relieving composition containing nostoc sphaeroides and preparation method and application thereof | |
| CN109498472B (en) | Soft and moist deep cleansing gel and preparation method thereof | |
| KR101852510B1 (en) | Cosmetic Composition Containing Broussonetia Extract for Inhibiting Lipogenesis and Decreasing Sebum Secretion of Skin | |
| CN115607490B (en) | Skin care composition for inhibiting sebaceous gland inflammation and preparation method thereof | |
| CN115607490A (en) | Skin care composition for inhibiting sebaceous gland inflammation and preparation method thereof | |
| CN110917052A (en) | Coconut oil-containing moisturizing mask liquid, preparation method thereof and patch mask | |
| CN115414308A (en) | Acne removing composition as well as preparation method and application thereof | |
| CN105342966A (en) | Skin care moisturizer containing hirudo nipponia and preparation method of skin care moisturizer | |
| KR20160036834A (en) | Skin external application composition comprising complex fermented extract of crude drug ingredients | |
| CN115364039A (en) | Acne skin repairing composition and application thereof | |
| CN115337233A (en) | Gel mask with mild acne removing effect and preparation method thereof | |
| CN108619017A (en) | A kind of Tianshan Mountains snow chrysanthemum skin care compositions and its application | |
| CN114272184A (en) | Polypeptide composition, anti-aging repair eye cream containing polypeptide composition and preparation method of anti-aging repair eye cream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |